Yahoo Web Search

Search results

    • AbbVie Completes Acquisition of Landos Biopharma

      Valley City Times Record· 1 day ago

      With the completion of the acquisition, Landos is now part of AbbVie. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like ...

    • 2 Billion More Reasons to Buy AbbVie Stock

      2 Billion More Reasons to Buy AbbVie Stock

      Motley Fool via Yahoo Finance· 2 days ago

      There are plenty of reasons to buy a leading biopharma business like AbbVie (NYSE: ABBV), and investors just got at least a few more. Thanks to a large...